ScreenerHero

CRVO CervoMed Inc.

NAS · US · Healthcare · Biotechnology · cervomed.com
3.180USD-4.79%Mkt Cap: 48.08M $P/E: —

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered s…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap48.08M USD
Enterprise Value25.56M USD
Revenue (TTM)331.30K USD
Gross Profit-21.00M USD
Net Income (TTM)-26.97M USD
Revenue/Share0.04 USD
Last Price3.180 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees15
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.26
PEG—
EV/EBITDA—
EV/Revenue77.15
P/S152.43
P/B1.97
EPS (TTM)-3.22
EPS (Forward)-1.48
52W Range
2.14513% of range10.00
52W High10.00 USD
52W Low2.145 USD
Profitability
Gross Margin0.00%
Oper. Margin-9406.96%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-147.98%
ROA-117.87%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.45M USD
CapEx (TTM)—
FCF Margin-4916.94%
FCF Yield-33.88%
Net Debt-24.94M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio8.57
Quick Ratio8.22
Book Value/Sh1.70 USD
Cash/Share1.65 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateDec 14, 2018
Splits
Last Split2:3
Split DateAug 17, 2023
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)15.40 USD
Upside (mean)+384.3%
Target Range7.000 USD – 25.00 USD
7.000+384.3% to mean25.00
# Analysts5
Ownership
Shares Out.15.12M
Float9.60M
Insiders26.43%
Institutions22.29%
Short Interest
Short Ratio5.3d
Short % Float10.04%
Short % Out.8.12%
Shares Short1.23M
Short (prev mo.)962.58K
Technical
SMA 502.680 (+18.7%)
SMA 2004.002 (-20.5%)
Beta-4.30
S&P 52W Chg16.45%
Avg Vol (30d)239.62K
Avg Vol (10d)284.53K
Technical Indicators
RSI (14)65.5
MACD0.1371
MACD Signal0.0472
MACD Hist.+0.0899
BB Upper3.326 USD
BB Middle2.715 USD
BB Lower2.104 USD
BB Width45.04%
ATR (14)0.1892 USD
Vol Ratio (20d)1.37x